Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.
about
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesLung Cancer Gene Signatures and Clinical PerspectivesQSAR based model for discriminating EGFR inhibitors and non-inhibitors using Random forestStrategies for modern biomarker and drug development in oncology.Molecular pathways and therapeutic targets in lung cancerSequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR.Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinomaThe HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.DNA methylation and RNA expression profiles in lung adenocarcinomas of never-smokers.Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer.Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancerEGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma.Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis.Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening.A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non-Small Cell Lung Cancer Cells.Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective studyDUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive propertiesClinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspectiveAdvances towards the design and development of personalized non-small-cell lung cancer drug therapy.Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments.Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer.The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type.A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case reportA randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.Lung surgery in interstitial lung disease-a safe and useful procedure?Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy.Human genetics as a foundation for innovative drug development.Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR.Polymorphisms in genes related to epithelial-mesenchymal transition and risk of non-small cell lung cancer.Prognostic significance of epidermal growth factor receptor expression in glioma patients.A targetable HB-EGF-CITED4 axis controls oncogenesis in lung cancer.
P2860
Q26797297-C2C8B8C7-BDB7-47AB-BD6E-A9EE0C4EED69Q28387769-6422C856-3599-4BDB-BE93-94890DD73ECDQ28544930-530E6195-213F-471B-B247-6053383B3775Q30590270-16629475-9E14-4BCA-8F88-2917ECDA9A75Q33688872-5CF7CC41-30C3-4FB5-B3D7-531B7A61987DQ33995172-1BF655BB-A52A-497E-915A-0D9552A55B9EQ34101040-8F86B93E-9C40-488E-B27A-18CB30C4191AQ34581688-44263E48-D7CC-4F3F-9FDC-FB0CB5719CD6Q35016510-090C55E3-D705-49D6-B798-136E93FDD4BAQ35077521-6703FDA1-8B38-43B3-8502-6FC49288F0EBQ35689752-2C87B3CE-A311-4CA8-BF4F-093365B17A44Q35738383-B8757DF3-186E-4DF5-B92E-2CB967C3B8FEQ35891380-5673E585-F1B8-4DD4-AB34-0443F6F67025Q36022297-2EC5A524-9715-467A-BDEC-BE5C24EF733BQ36208467-55C6B743-1AD3-418B-A85D-C21DCE7007BEQ36352476-D3ADFC4D-B23B-4737-95AD-F1A72E3185D4Q36438421-D1C6B5ED-59D5-4B26-9B43-6F15697C1404Q36823866-F996C80F-B2EA-4F87-B6C3-933C19E21B47Q36924484-F39E90EF-8BAC-470F-81B2-7C91C60489DEQ36999705-84993AAC-831D-4235-8FDC-983B73F5E6C2Q37074930-4DA0A5AB-805F-4DA1-AF80-0B859CD7769FQ37426768-DB3EF08A-9B13-4C3C-9894-296F2B1EF060Q37580148-F07BA3F5-A189-4B0F-A96F-EDB7B22D7284Q38148583-FDAEC223-CAC2-4608-A973-E260A50B919FQ38155932-822535A9-3065-4FC0-82B5-D740491750B2Q38289406-3CC81722-999F-4F7B-B2CA-814B415C1446Q38701670-72B1C209-F8AF-4AC4-BF40-9150188C1B88Q38705129-5CC312D6-193C-42CE-8DF1-6C5467B11995Q40701318-8B9911B5-A022-45C8-B867-A1D32C5087F8Q40977709-284EAFDC-7E3D-4D77-B2A1-9161124B3FCAQ41027999-5FE2B8ED-72B1-409D-AE06-5A3820E43552Q41521400-4CE6B555-9B1D-4EE4-9E8C-E82F389D4D79Q41755815-9EBB5873-64F3-4CB1-BE71-71240106AD3BQ42094692-7CBD8781-7131-4DC8-AE4F-DA195C43463BQ42371658-655A8245-1A8E-46A3-8A2B-7AF714BF835AQ46007453-80DF31A4-37BE-4261-85D2-C1E66D479B6BQ46603973-87C4611D-F09A-452E-8EF1-708E7E156314Q47254894-8BB6EB78-BD8A-4315-BD83-1668B4AB04D4Q50200201-1A18E585-D7E2-4472-9C79-A21396A0FE18Q51042385-6DEBD1A7-F248-4762-A5F7-72F32298FBFB
P2860
Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Role of epidermal growth facto ...... pe non-small-cell lung cancer.
@en
type
label
Role of epidermal growth facto ...... pe non-small-cell lung cancer.
@en
prefLabel
Role of epidermal growth facto ...... pe non-small-cell lung cancer.
@en
P356
P1476
Role of epidermal growth facto ...... pe non-small-cell lung cancer.
@en
P2093
Glenwood D Goss
Scott A Laurie
P304
P356
10.1200/JCO.2012.43.4522
P407
P577
2013-02-11T00:00:00Z